How treatment by Mounjaro works — from first dose to ongoing care

Step 1: Understanding what Mounjaro is, and clearing up a common confusion

A lot of people arrive asking about Mounjaro having heard it described as "the same as Ozempic." It isn't. Both involve gut-hormone pathways, but Ozempic (semaglutide) targets the GLP-1 receptor only and is licensed in the UK for type 2 diabetes, not weight loss. Mounjaro activates two receptors at once, GIP and GLP-1, which is why you'll see it described as a dual agonist. That distinction matters clinically and explains some of the difference in trial results.

The mechanism itself is worth understanding because it shapes what you experience on treatment. By activating both receptors, tirzepatide slows how quickly the stomach empties, reduces hunger signals from the brain, and influences insulin release after meals. The result isn't a dramatic suppression but a gradual recalibration of appetite, most people find food simply stops being as consuming a thought. The NHS medicines page on tirzepatide explains the pharmacology clearly alongside what to expect day to day. For a closer look at the manufacturer's background, our page on who makes Mounjaro covers Eli Lilly's role and the UK supply chain.

As a prescription-only medicine, it cannot legally be dispensed without a clinical assessment. That step isn't a formality, it's where contraindications, current medications, and your full health picture are reviewed by a qualified prescriber before anything is issued.

Step 2: The dose schedule and what each stage is actually for

Mounjaro is supplied in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15mg. Treatment begins at 2.5mg, not because that dose has a large therapeutic effect on its own, but because your digestive system needs time to settle before moving up. The first four weeks are mostly about adjustment. Nausea, loose stools, and fatigue are most likely to appear when starting or after a dose increase, and they tend to ease within days to a couple of weeks as the body adapts.

After that, a prescriber typically considers moving to the next strength in four-week steps, though the exact pace depends on tolerability and clinical assessment. The decision to increase a dose is never automatic, at nume, each step is reviewed before a new pen is issued. Our week-by-week Mounjaro guide goes into more detail on what people typically notice at different stages, and our day-by-day breakdown covers the early adjustment period more precisely.

Each KwikPen holds four doses, so one pen covers a month of treatment. You inject subcutaneously (just under the skin) into the abdomen, thigh, or upper arm, rotating the site each week. Storage is in the fridge between 2–8°C; the patient information leaflet sets out the exact room-temperature window if you need to travel.

Step 3: Tracking progress and knowing what results by Mounjaro look like in practice

The headline trial figures are cited often enough that they can start to feel abstract. What they actually represent: in SURMOUNT-1, a 72-week study published in the New England Journal of Medicine, adults with obesity using the 15mg dose lost an average of roughly 20–21% of their body weight alongside a reduced-calorie diet and increased physical activity. That's a meaningful clinical outcome, not a promise about any individual. Results vary by starting weight, diet, activity, and the dose reached.

Weight loss also doesn't arrive in a straight line. The first few weeks are often quiet, your body is still adjusting, and appetite changes are subtle. Noticeable progress tends to build from around weeks six to twelve onward. Our Mounjaro weight loss by week page maps that trajectory in more detail, drawing from the trial data rather than anecdote.

If you're wondering about the more detailed science (including whether tirzepatide has any effects beyond the gut) our page on how tirzepatide interacts with the brain covers what the research currently shows. NICE's appraisal of tirzepatide (TA1026) also includes the full evidence review for those who want the clinical detail. For current private pricing context, the Mounjaro treatment page sets out what's included in a single transparent cost.

Step 4: Safety, side effects, and what to do if something doesn't feel right

The side-effect profile is well characterised. Gastrointestinal effects (queasiness, changes in bowel habits, reflux, reduced appetite to the point of forgetting meals) are the most common, particularly in the opening weeks or after stepping up in dose. They are mostly mild to moderate and temporary, though for a minority they're disruptive enough to slow the dose increase or require a conversation with the prescribing team.

A handful of effects need prompt attention rather than watchful waiting. Severe stomach pain that moves toward the back, with or without vomiting, should prompt medical help the same day, the MHRA's guidance on GLP-1 medicines, updated in early 2026, highlights acute pancreatitis as an infrequent but serious risk across this drug class. Gallbladder symptoms, signs of an allergic reaction, and significant mood changes are also reasons to contact a clinician rather than sit it out.

Contraception is worth raising specifically: if you take an oral contraceptive pill, adding a non-oral method for the first four weeks of Mounjaro treatment and for four weeks after each dose increase is recommended, because absorption of the pill may be reduced during that window. This applies to tirzepatide specifically; NHS England's guidance on weight management injections covers this and other practical considerations including HRT and surgery. If you have questions about your specific situation, our prescribing team is reachable through the support page seven days a week.

Ready to find out whether Mounjaro is suitable for you? Start your free consultation and a GPhC-registered prescriber will review your answers the same day.